HIGHLIGHTS
- who: Ryon P. Graf et al. from the The Keynote, study paradoxically did not show superiority of adding pemFoundation Medicine, Cambridge, Massachusetts, Upstate Medical University, Syracuse, New York. , Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts. have published the research: OPEN ACCESS, in the Journal: (JOURNAL) of 17/Nov/2022
- what: The authors focused primarily on TMB, given existing predictive clinical validity and cross-platform harmonizations , using the same platform (Foundation Medicine) and cutoff of 10 mut/Mb as the existing FDA CDx for pembrolizumab . were linked to genomic data derived . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.